Molecular biology progress of small cell lung cancer
10.3760/cma.j.issn.1673-422X.2018.02.013
- VernacularTitle:小细胞肺癌的分子生物学研究进展
- Author:
Ling MENG
1
;
Yongchang WEI
;
Conghua XIE
Author Information
1. 430071,武汉大学中南医院肿瘤放化疗科
- Keywords:
Carcinoma,small cell;
Immunotherapy;
Targeted therapy
- From:
Journal of International Oncology
2018;45(2):115-118
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is typified by early recurrence and metastasis associated with many genetic changes.The drug ROVA-T composed of the DLL3 antibody Rovalpituzumab and the cytotoxic drug Tesirine achieves the tumor-killing effect by releasing the Tesirine when bound to DLL3.Nfib promotes the SCLC metastasis by altering the structure of the chromosome.The PRAP,EZH2 and Weel inhibitors inhibit the DNA damage repair to improve the antitumor activity of chemotherapeutic drugs.Combination of Ipilimumab and Nivolumab can activate the human immune system to exert antitumor effect.
